Literature DB >> 11918509

Severe interaction between ritonavir and acenocoumarol.

Josep M Llibre1, Joan Romeu, Estibaliz López, Guillem Sirera.   

Abstract

OBJECTIVE: To report a clinically severe interaction between ritonavir (RTV) and acenocoumarol resulting in a decrease in the anticoagulant effect severe enough to eventually preclude RTV administration. CASE
SUMMARY: An asymptomatic, HIV-infected, 46-year-old man with mitraortic prosthetic valves receiving acenocoumarol therapy started stavudine, lamivudine, and RTV 600 mg twice daily. His international normalized ratio (INR) decreased dramatically (the opposite of what should be expected). Although the acenocoumarol dose was progressively increased to 3 times the original dose, it was impossible to achieve the previous INR and RTV was withdrawn. DISCUSSION: RTV is an inducer of the hepatic isoenzymes CYP1A2, CYP1A4, and CYP2C9/19 and leads to extensive metabolism of acenocoumarol that cannot be balanced by dose increases. This effect is the opposite of what was expected to occur, considering that RTV is also a strong inhibitor of most hepatic isoenzymes.
CONCLUSIONS: RTV severely decreases the anticoagulant effect of acenocoumarol. It must be added to the list of drugs that affect the action of oral anticoagulants, and it probably should be avoided in patients receiving acenocoumarol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918509     DOI: 10.1345/aph.19361

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far.

Authors:  José Antonio Morales-Molina; Juan Enrique Martínez-de la Plata; Olivia Urquízar-Rodríguez; María Angustias Molina-Arrebola
Journal:  Hematol Rep       Date:  2011-10-10

Review 2.  Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.

Authors:  Shubham Agarwal; Sanjeev Kumar Agarwal
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-12       Impact factor: 3.727

Review 3.  Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.

Authors:  Catherine Hodge; Fiona Marra; Catia Marzolini; Alison Boyle; Sara Gibbons; Marco Siccardi; David Burger; David Back; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.